Sanofi is assessing a potential acquisition of US respiratory disease drugmaker Insmed as it looks for new growth drivers beyond blockbuster Dupixent. Insmed shares jumped on Thursday after news of the discussions emerged, while Sanofi stock fell. No offer or deal terms have been announced.
Sanofi examines a possible Insmed acquisition
Sanofi is working with advisers to assess whether a deal for Insmed could make sense. The talks remain at an exploratory stage, with no disclosed price or indication that Sanofi will formally pursue an offer. For new Chief Executive Belén Garijo, a potential acquisition would be one route to finding another major growth product as the company adjusts its sources of revenue.
Insmed focuses on respiratory diseases and has two marketed medicines. Brinsupri (brensocatib) treats non-cystic fibrosis bronchiectasis, while Arikayce (amikacin liposome inhalation suspension) is used to treat refractory Mycobacterium avium complex (MAC) lung disease.
Brinsupri sales underpin Insmed's growth case
Insmed reported third-quarter Brinsupri sales of $400.1 million and Arikayce sales of $124.4 million. The company expects Brinsupri revenue of $1.35 billion to $1.4 billion in 2026, and Arikayce sales of $460 million to $470 million. Current revenue and those growth forecasts are central to the commercial case for a potential acquisition.
Insmed's pipeline also includes TPIP, an inhaled treprostinil palmitil powder being developed for four lung diseases. Earlier-stage programmes include INS1148, INS1033 and a next-generation DPP1 inhibitor.
In July, Insmed reported 12-month results from an open-label extension study of TPIP in patients with pulmonary arterial hypertension. Several measures of efficacy continued to improve, with similar benefits among patients who had initially received placebo before switching to TPIP. In March, the company reported preliminary results from the Phase IIIb ENCORE study of Arikayce, which met its primary and all secondary endpoints when used with a multidrug regimen.
Insmed Chief Financial Officer Sara Bonstein left the company on October 30 after nearly seven years in the role. Available information does not link her departure to the acquisition assessment.
Dupixent's patent timeline sharpens Sanofi's focus
Dupixent, which treats inflammatory conditions including eczema and asthma, is one of Sanofi's key products. As its patent protection approaches expiration, investors are watching how the company might address a potential future revenue gap, including through acquisitions of late-stage drug candidates.
On its second-quarter earnings call, Sanofi said it would take a more disciplined approach to research and development. Garijo attributed recent pipeline setbacks to poor decision-making rather than a lack of scientific capability. She said the company was reviewing its portfolio and had not ruled out discontinuing additional drug candidates. Sanofi said it would prioritise programmes with strong scientific rationale, significant unmet medical need and commercial potential.
Sanofi's challenge is to build new sources of growth while Dupixent remains commercially important. Insmed would bring marketed medicines, projected revenue growth and further development programmes, but any transaction will depend on Sanofi's assessment and subsequent action by the companies.
As of Thursday, Insmed was up 18.43% at $141.87, while Sanofi was down 2.05% at $46.15. The share moves reflected the market's immediate reaction to the potential deal; no acquisition agreement had been announced.